Skip to content

Clinical Randomized Controlled Pilot Trial of Novel Drug-Delivery Photodynamic Therapy and Laser Combined with Photodynamic Therapy for the Treatment of Refractory Cutaneous Warts

Clinical Randomized Controlled Trial of Novel Drug-Delivery Photodynamic Therapy and superpulsed CO2 Laser Combined with Photodynamic Therapy for the Treatment of Refractory Cutaneous Warts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101799
Enrollment
Unknown
Registered
2025-04-29
Start date
2025-01-02
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common wart and plantar wart

Interventions

Superpulsed CO2 laser combined with ALA-PDT group:Superpulsed CO2 laser combined with ALA-PDT
Novel Drug-Delivery Photodynamic Therapy group(Intralesional injection photodynamic therapy group):Novel Drug-Delivery Photodynamic Therapy (Intralesional injection photodynamic therapy)

Sponsors

Huadong Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 10 and 80 years old, regardless of gender. 2. Clinical diagnosis of common warts or plantar warts. 3. Duration of the disease >=2 years or previous treatment with multiple therapeutic methods with unsatisfactory results. 4. Have not received systemic or topical antiviral and immunotherapy within 2 months prior to enrollment. 5. The patient has signed an informed consent form and agreed to be followed up regularly.

Exclusion criteria

Exclusion criteria: 1. Known history of allergy to red-light or ALA. 2. History of severe hypertrophic scar or keloids. 3. Those with significant bleeding tendency. 4. Patients with psychological disorders such as blood or trauma phobia. 5. Patients with other diseases that may affect the evaluation of the efficacy of the treatment. 6. Those with severe immunocompromise; 7. Those suffering from serious internal diseases. 8. Pregnant or lactating women; 9. Other patients who, in the opinion of the investigator, are not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
percentage of viral wart volume reduction;

Secondary

MeasureTime frame
safety;Relapsing rate;Mechanism exploration;effective rate;cure rate;

Countries

China

Contacts

Public ContactLei Shi

Huadong Hospital, Fudan University

leishinsh@163.com+86 21 6248 3180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026